Macromolecular Therapeutics: Advantages and Prospects with Special Emphasis on Solid Tumour Targeting

Clinical Pharmacokinetics

Volumn 42, Issue 13, 2003, Pages 1089-1105

  Greish, Khaled ^a   Fang, Jun ^a   Inutsuka, Takao ^a   Nagamitsu, Akinori ^b   Maeda, Hiroshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Kumamoto Junkanki ka Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ABDOMINAL PAIN; ANAPHYLAXIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASCITES; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EXCRETION; DRUG HALF LIFE; DRUG UPTAKE; FEVER; HUMAN; HYPOTENSION; KIDNEY DISEASE; LEUKOCYTOSIS; LEUKOPENIA; LIVER DISEASE; NAUSEA; NEUTROPENIA; NEUTROPHILIA; PRIORITY JOURNAL; RASH; REVIEW; RIGOR; SKIN MANIFESTATION; SOLID TUMOR; THORAX PAIN; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MACROMOLECULAR SUBSTANCES; NEOPLASMS; POLYMERS;

EID: 0242288519     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342130-00002     Document Type: Review

References (123)

1. World Health Organization. Press release WHO/52, 28 June 2002. Available online from: http://www.who.int/inf/en/ pr-2002-52.html [Accessed 2003 Aug 23]
2. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumor tropic accumulation of proteins and antitumor agent SMA-neocarzinostatin. Cancer Res 1986; 46: 6387-92
3. Noguchi Y, Wu J, Duncan R, et al. Early phase of tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 1998; 89: 307-14
4. Iwai K, Maeda H, Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res 1984; 44: 2114-21
5. Folkman J. Tumor angiogenesis in cancer, therapeutic implications. N Engl J Med 1971; 285: 1182-6
6. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31
7. Wu J, Akaike T, Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res 1998; 58: 159-65
8. Maeda H, Akaike T, Wu J, et al. Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology 1996; 33: 222-30
9. Matsumura Y, Kimura M, Yamamoto T, et al. Involvement of the kinin-generating cascade and enhanced vascular permeability in tumor tissue. Jpn J Cancer Res 1988; 79: 1327-34
10. Maeda H, Matsumura Y, Kato H. Purification and identification of [hydroxypropyl 3] bradykinin in ascitic fluid from a patient with gastric cancer. Jpn J Cancer Res 1994; 85: 331-4
11. Doi K, Akaike T, Horie H, et al. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer 1996; 77: 1598-04
12. Doi K, Akaike T, Fujii S, et al. Induction of haem oxygenase-1 by nitric oxide and ischaemia in experimental solid tumors and implications for tumor growth. Br J Cancer 1999; 80: 1945-54
13. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5
14. Wu J, Akaike T, Hyashida K, et al. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J Cancer Res 2001; 92; 439-51
15. Arshady R, editor. Polymeric biomaterials, the PBM Series, Vol 1; introduction to polymeric biomaterials. London: Citus Books, 2003: 233-61
16. Maeda H, Kabanov A, Kataoka K, et al., editors. Polymer drugs in the clinical stage: advantages and prospects. New York: Kluwer Academic, 2003
17. Schechter B, Neumann A, Wilchek M, et al. Soluble polymers as carriers of cisplatinum. J Control Release 1989; 10: 75-87
18. Li C, Yu DF, Newman R, et al. Complete regression of well-established tumors using a novel water-soluble poly (L-glutamic acid)-paclitaxel conjugate. Cancer Res 1998; 58: 2404-9
19. Singer JW, De Vries P, Bhatt R, et al. Conjugation of camptothecins to poly-(L-glutamic acid). Ann N Y Acad Sci 2000; 922: 136-50
20. Al-Shamkhani A, Duncan R. Alginates as a macromolecular drug delivery system for the antitumor agent daunomycin: synthesis, controlled release properties and antitumor activity of alginate-cis-aconityl-daunomycin conjugates. Int J Pharm 1995; 122: 107-19
21. Ohya Y, Inosaka K, Ouchi T. Synthesis and antitumor activity of 6-O-carboxymethyl chitin fixing 5-fluorouracil through pentamethylene, monomethylene spacer groups via amide, ester bonds. Chem Pharm Bull (Tokyo) 1992; 40: 559-61
22. Yashima E, Uchida S, Akashi M, et al. Polymer drugs and polymeric drugs. Part VII. Antitumour conjugated polymeric drugs consisting of 5-fluorouracil and polyanionic polymers. J Bioact Compat Polym 1990; 5: 53-64
23. Danhauser-Riedl S, Hausmann E, Schick HD, et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs 1993; 11: 187-95
24. Munechika K, Sogame Y, Kishi N, et al. Tissue distribution of macromolecular conjugate adriamycin linked to oxidized dextran, in rat and mouse bearing tumor-cells. Biol Pharm Bull 1994; 17; 1193-8
25. Bernstein A, Hurwitz E, Arnon R. Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies. J Natl Cancer Inst 1978; 60: 379-84
26. Takakura Y, Atsumi R, Hashida M, et al. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge: II. disposition and pharmacokinetics following intravenous and intramuscular administration. Int J Pharm 1987; 37: 145-54
27. Takakura Y, Kitajima M, Matsumoto S, et al. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge: I. physicochemical characteristics and in vivo and in vitro antitumour activities. Int J Pharm 1987; 37: 135-43
28. Okuno S, Harada M, Yano T, et al. Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res 2000; 60: 2988-95
29. Schechter B, Pauzner R, Arnon R, et al. Cisplatinum (II) complexes of carboxymethyl dextran as potential antitumor agents: I. Preparation and characterization. Cancer Biochem Biophys 1986; 8: 277-87
30. Ichinose K, Tomiyama N, Nakashima M, et al. Antitumor activity of dextran derivatives immobilizing platinum complex (II). Anticancer Drugs 2000; 11: 33-8
31. Nogusa H, Yano T, Okuno S, et al. Synthesis of carboxymethylpullulan- peptide-doxorubicin conjugates and their properties. Chem Pharm Bull 1995; 43: 1931-6
32. Nogusa H, Hamana H, Uchida N, et al. Improved in vivo antitumor efficacy and reduced systemic toxicity of carboxymethylpullulan-peptide-doxorubicin conjugates. Jpn J Cancer Res 2000; 91: 1333-8
33. Hirano T, Ringsdorf H, Zaharko D. Antitumor activity of monomeric and polymeric cyclophosphamide derivative compound with in vitro hydrolysis. Cancer Res 1980; 40: 2263-7
34. Pratesi G, Tortoreto M, Zunino F. Increased effect of doxorubicin linked to pyran copolymer in the intracavity treatment of human ovarian carcinoma in nude mice. Reg Cancer Treat 1990; 3: 40-3
35. Duncan R, Hume IC, Yardley HJ, et al. Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N-(2-hydroxypropyl) methacrylamide copolymers. J Control Release 1991; 16: 121-36
36. Putnam DA, Kopecek J. Enantioselective release of 5-fluorouracil from N-(2-hydroxypropyl) methacrylamide-based copolymers via lysosomal enzymes. Bioconjug Chem 1995; 6: 483-92
37. Vasey P, Kaye S, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 1999; 5: 83-94
38. Kopecek J, Kopeckova P, Minko T, et al. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 2000; 50: 61-81
39. Caiolfa VR, Zamai M, Fiorino A, et al. Polymer-bound camptothecin: initial biodistribution and antitumor activity studies. J Control Rel 2000; 65: 105-19
40. Greenwald RB, Gilbert CW, Pendri A, et al. Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs -design and in vivo effectiveness. J Med Chem 1996; 39: 424-31
41. Li C, Yu D, Inoue T, et al. Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug. Anticancer Drugs 1996; 7: 642-8
42. Pendri A, Conover CD, Greenwald RB. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly (ethylene glycol): a water-soluble prodrug. Anticancer Drug Des 1998; 13: 387-95
43. Zhang X, Burt HM, Mangold G, et al. Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel. Anticancer Drugs 1997; 8: 696-01
44. Ramaswamy M, Zhang X, Burt HM, et al. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J Pharm Sci 1997; 86: 460-4
45. Zhang X, Burt HM, Von Hoff D, et al. An investigation of the antitumor activity and biodistribution of polymeric micellar paclitaxel. Cancer Chemother Pharmacol 1997; 40: 81-6
46. Mizumura Y, Matsumura Y, Hamaguchi T, et al. Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res 2001; 92: 328-36
47. Yokoyama M, Miyauchi M, Yamada N, et al. Characterization and antitumor activity of the micelle-forming polymeric anticancer drug doxorubicin- conjugated poly (ethylene glycol)-poly (aspartic acid) block copolymer. Cancer Res 1990; 50: 1693-00
48. Yokoyama M, Okano T, Sakurai Y, et al. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res 1991; 51: 3229-36
49. Yokoyama M, Okano T, Sakurai Y, et al. Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. J Drug Target 1999; 7: 171-86
50. Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 2002 Sep 13; 54: 715-58
51. Fischer D, Li Y, Ahlemeyer B, et al. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003; 24: 1121-31
52. Kopecek J, Kopeckova P, Minko T, et al. Water-soluble polymers in tumor targeted delivery. J Control Release 2001 Jul 6; 74: 147-58
53. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001; 19: 424-36
54. Brocchini S, Duncan R. Pendent drugs, release from polymers. In: Mathiowitz E, editor. Encyclopedia of controlled drug delivery. New York: John Wiley & Sons Inc, 1999: 786-816
55. Sawa T, Sahoo SK, Maeda H. Water-soluble polymer in medicine. In: Arshady R, editor. Polymeric biomaterials, The PBM Series, Vol 1: introduction to polymeric biomaterials. London: Citus Books, 2003: 233-61
56. Maeda H, Matsumura Y, Oda T, et al. Cancer selective macromolecular therapeutics: tailoring of an antitumor protein drug. In: Feeny RE, Whitaker JR, editors. Protein tailoring for food and medical uses. New York: Marcel Dekker Inc, 1986: 353-82
57. Maeda H, Takeshita J, Kimura M. Improvement of pharmacological properties of protein drugs by tailoring with synthetic polymers. J Bioact Compat Polym 1988; 3: 27-43
58. Bartholeyns J, Moore S. Pancreatic ribonuclease: enzymatic and physiological properties of cross-linked dimer. Science 1974; 186: 444-5
59. Takakura T, Kaneko Y, Hashida M, et al. Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran: I. synthesis and characterization. J Pharm Sci 1989; 78: 117-21
60. Takakura T, Fujita T, Hashida M, et al. Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran II. Biopharmaceutical and pharmacological properties. J Pharm Sci 1989; 78: 219-22
61. Ogino T, Inoue M, Ando Y, et al. Chemical modification of superoxide dismutase: extension of plasma half-life of the enzyme through its reversible binding to the circulating albumin. Int J Pept Protein Res 1988; 32: 153-9
62. Kimura M, Matsumora Y, Miyauchi Y, et al. A new tactic for the treatment of jaundice: an injectable polymer-conjugated bilirubin oxidase. Pro Soc Exp Biol Med 1988; 188: 364-9
63. Buys CHCM, Dejong ASH, Bouma JDW, et al. Rapid uptake by liver sinusoidal cells of serum albumin modified with retention of its compact conformation. Biochim Biophys Acta 1975; 392: 95-100
64. Kamisaki Y, Wada H, Yagura H, et al. Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxy polyethylene glycol. J Pharmacol Exp Ther 1981; 216: 410-4
65. 2-macroglobulin-plasmin complex. Biochemistry 1985; 24: 4586-92
66. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990; 19: 390-9
67. Glue P, Fang J, Sabo WS, et al. Pegylated interferon-α2b: pharmacokinetics, pharmaco-dynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68: 556-67
68. Heathcote EJ, Shiffman ML, Coooksley WG, et al. PEG-interferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80
69. Duncan R, Rejmanova P, Kopecek J, et al. Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl) methacrylamide copolymers: a potential drug delivery system. Biochim Biophys Acta 1981; 678: 143-50
70. Maeda H, Aikawa S, Yamashita A. Subcellular fate of protein antibiotic neocarzinostatin in culture of lymphoid cell line from Burkett's lymphoma. Cancer Res 1975; 35: 554-9
71. Oda T, Maeda H. Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its action by conjugation with lipophilic styrene-maleic acid copolymer. Cancer Res 1987; 47: 3206-11
72. Pellegrin P, Fernandez A, Lamb NJ, et al. Macromolecular uptake is a spontaneous event during mitosis in cultured fibroblasts: implications for vector-dependent plasmid transfection. Mol Biol Cell 2002; 13: 570-8
73. Miyamoto Y, Oda T, Maeda H. Comparison of the cytotoxic effects of the high-and low-molecular-weight anticancer agents on multidrug-resistant Chinese hamster ovary cells in vitro. Cancer Res 1990; 150: 1571-5
74. St'astny M, Strohalm J, Plocova D, et al. Possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier. Eur J Cancer 1999; 35: 459-66
75. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990 Jan 3; 82: 4-6
76. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001; 74: 47-61
77. Maeda H. Enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189-07
78. Maeda H, Fang J, Inuzuka T, et al. Vascular permeability enhancement in solid tumors: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003; 3: 319-28
79. Jain R. Barriers to drug delivery in solid tumors. Sci Am 1994; 271: 58-65
80. Seymour LW, Miyamoto Y, Maeda H, et al. Influence of molecular weight on passive tumor accumulation of a soluble macromolecular drug carrier. Eur J Cancer 1995; 31A: 766-70
81. Duncan R. Polymer conjugates for tumor targeting and intercytoplasmic delivery: the EPR effect as a common gateaway? Pharm Sci Technol Today 1999; 2 (11): 441-9
82. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55: 3752-6
83. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156: 1363-80
84. Ohkouchi K, Imoto H, Takakura Y, et al. Disposition of anticancer drugs after bolus arterial administration in a tissue-isolated tumor perfusion system. Cancer Res 1990; 50: 4396-401
85. Konno T, Maeda H, Iwai K, et al. Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 1984; 54: 2367-74
86. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 1991; 6: 181-02
87. Iwai K, Maeda H, Konno T, et al. Tumor targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver. Anticancer Res 1987; 7: 321-7
88. Marecos E, Weissleder R, Bogdanov A. Antibody-mediated versus nontargeted delivery in a human small cell lung carcinoma model. Bioconjug Chem 1998; 9: 184-91
89. Skinner S, Tutton P, O'Brien PE. Microvascular architecture of experimental colon tumors in the rat. Cancer Res 1990; 50: 2411-7
90. Suzuki M, Takahashi T, Sato T. Medial regression and its functional significance in tumor supplying host arteries. Cancer 1987; 59: 444-50
91. Li CJ, Miyamoto Y, Kojima Y, et al. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br J Cancer 1993; 67: 975-80
92. Maeda H, Wu J, Okamoto T, et al. Kallikrein-kinin in infection and cancer. Immunopharmacology 1999; 43: 115-28
93. Suzuki M, Hori K, Abe Z, et al. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 1981; 67: 663-9
94. Hori K, Saito S, Takahashi H, et al. Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn J Cancer Res 2000; 91: 261-9
95. Hori K, Suzuki M, Tanda S, et al. Fluctuation in tumor blood flow under normotension and the effect of angiotensin-II induced hypertension. Jpn J Cancer Res 1991; 82: 1309-16
96. Wu J, Akaike T, Hayashida K, et al. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 2002; 98: 29-35
97. Kamata R, Yamamoto T, Matsumoto K, et al. A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pig. Infect Immun 1985; 48: 747-53
98. 2analogue, beraprost sodium. J Drug Target 2003; 11: 45-52
99. Yamaguchi T, Takahashi T, Kitamura K, et al. Application of tumor marker for immunotargeting therapy of cancer. Nippon Rinsho 1996; 54: 1674-9
100. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2: 750-63
101. Ranson M, Sliwkowski MX. Perspectives on anti-HER monoclonal antibodies. Oncology 2002; 63 Suppl. 1: 17-24
102. King KM, Younes A. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 2001; 1: 177-86
103. Maeda H. Neocarzinostatin in cancer chemotherapy (review). Anticancer Res 1981; 1: 175-86
104. Edo K, Koide Y. Neocarzinostatin chromophore: structure and mechanism of DNA cleavage. In: Maeda H, Edo K, Ishida N, editors. Neocarzinostatin: the past, present, and future of an anticancer drug. Tokyo: Springer-Verlag, 1997: 23-45
105. Maeda H, Ueda M, Morinaga T, et al. Conjugation of poly(styrene-co- maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J Med Chem 1985; 28: 455-61
106. Oda T, Morinaga T, Maeda H. Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane. Proc Soc Exp Biol Med 1986; 181: 9-17
107. Oda T, Sato F, Maeda H. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH. J Natl Cancer Inst 1987; 79: 1205-11
108. Oka K, Miyamoto Y, Matsumura Y, et al. Enhanced intestinal absorption of a Hydrophobic polymer-conjugated protein drug, SMANCS, in an oily formulation. Pharm Res 1990; 7: 852-5
109. Kobayashi A, Oda T, Maeda H. Protein binding of macromolecular anticancer agent SMANCS: characterization of poly (styrene-co-maleic acid) derivatives as an albumin binding ligand. J Bioact Compat Polym 1988; 3: 319-33
110. Maeda H, Matsumoto T, Konno T, et al. Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on SMANCS. J Protein Chem 1984; 3: 181-93
111. Konno T, Maeda H, Iwai K, et al. Effect of arterial administration of high-molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 1983; 19: 1053-65
112. Maki S, Konno T, Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 1985; 56: 751-7
113. Konno T, Kai Y, Yamashita R, et al. Targeted chemotherapy for unresectable primary and metastatic liver cancer. Acta Oncol 1994; 33: 133-7
114. Seymour LW, Olliff SP, Poole CJ, et al. A novel dosage approach for evaluation of SMANCS in the treatment of primary hepatocellular carcinoma. Int J Oncol 1998; 12: 1217-23
115. Reddy K, Wright T, Pockros P, et al. Efficacy and safety of pegylated (40-kDa) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-8
116. Karasiewicz R, Nalin C, Rosen P. PEG-interferon conjugates, compound no. (Ro25-2854, Ro24-9485). US Patent 5,382,657. 1995 Jan 17
117. Rajender R, Modi M, Pedder S. Use of peginterferon α-2a (40KD) (Pegasys®) for the treatment of hepatitis C. Adv Drug Deliv Rev 2002; 54: 571-86
118. Fried M, Shiffman M, Reddy K, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82
119. Zeuzem S, Feinman SV, Rasenack J, et al. PEG-interferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-772
120. Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma. Cancer Invest 2002; 20: 859-60
121. Matsumora Y. An interim analysis of phase I clinical trial of MCC-456, doxorubicin encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. In: Maeda H, Kabanov A, Kataoka K, et al. editors. Polymer drugs in the clinical stage: advantages and prospects. New York: Kluwer Academic, 2003: 179-94
122. Hershfield MS, Buckley R, Greenberg M, et al. Treatment of adenosine deaminase deficiency with polyethylene glycolmodified adenosine deaminase. N Engl J Med 1987; 310: 586-9
123. Abuchowski A, Kazo G, Verhowest J, et al. Cancer therapy with chemically modified enzymes: I. antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 1984; 7: 175-86